Technical Analysis for CNST - Constellation Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
A 33.76 -0.18% -0.06
CNST closed down 0.18 percent on Friday, June 18, 2021, on 1.27 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat
Historical CNST trend table...

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup -0.24%
Pocket Pivot Bullish Swing Setup -0.24%
Volume Surge Other -0.24%
Calm After Storm Range Contraction -0.24%
Narrow Range Bar Range Contraction -0.24%
NR7 Range Contraction -0.24%
NR7-2 Range Contraction -0.24%
Parabolic Rise Strength -0.24%
Stochastic Reached Overbought Strength -0.24%
Wide Bands Range Expansion -0.24%
Older End-of-Day Signals for CNST ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Constellation Pharmaceuticals, Inc. Description

Constellation Pharmaceuticals, Inc. is a United States-based company, which discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, and the other program is evaluating a compound, CPI-1205. CPI-0610 is a small molecule that inhibits the binding of bromodomain and extra terminal (BET) proteins to chromatin. CPI-1205 is a small molecule that inhibits an enzyme, Enhancer of Zeste Homolog 2 (EZH2). It is in a Phase I clinical study of CPI-0610 in patients with progressive lymphoma; a Phase I clinical study of CPI-0610 in patients with acute leukemia, myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms; a Phase I clinical study of CPI-0610 in patients with previously treated multiple myeloma, and a Phase 1 clinical study of CPI-1205 in patients with lymphoma.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Diseases Treatment Of Cancer Lymphoma Multiple Myeloma Myelodysplastic Syndrome Constellation Progressive Molecule Therapeutics Acute Leukemia Neoplasms Chromatin Ezh2 Myeloproliferative Neoplasm

Is CNST a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.3
52 Week Low 17.0
Average Volume 1,562,055
200-Day Moving Average 26.07
50-Day Moving Average 24.36
20-Day Moving Average 28.89
10-Day Moving Average 33.70
Average True Range 0.88
ADX 52.93
+DI 51.30
-DI 10.56
Chandelier Exit (Long, 3 ATRs) 31.23
Chandelier Exit (Short, 3 ATRs) 22.06
Upper Bollinger Bands 42.03
Lower Bollinger Band 15.75
Percent B (%b) 0.69
BandWidth 90.97
MACD Line 3.22
MACD Signal Line 2.98
MACD Histogram 0.2458
Fundamentals Value
Market Cap 1.61 Billion
Num Shares 47.6 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -10.80
Price-to-Sales 0.00
Price-to-Book 2.77
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.90
Resistance 3 (R3) 33.91 33.86 33.88
Resistance 2 (R2) 33.86 33.83 33.86 33.87
Resistance 1 (R1) 33.81 33.80 33.79 33.81 33.86
Pivot Point 33.77 33.77 33.76 33.77 33.77
Support 1 (S1) 33.72 33.73 33.70 33.71 33.66
Support 2 (S2) 33.67 33.71 33.67 33.65
Support 3 (S3) 33.62 33.67 33.64
Support 4 (S4) 33.62